Inventizy Lab's stock is soaring on the morning of the 17th. This appears to be the result of registering a fundamental patent for the development of long-acting injection for obesity treatment.
A long-acting injection is a new type of pharmaceutical that replaces medication that must be taken daily with an injection every 1 to 3 months.
At 10:08 a.m. on that day, Inventizy Lab recorded a price jump to 17,350 won, reaching the price limit. The stock had been at a ceiling price since around 9:30 a.m.
That day, Inventizy Lab announced that it had secured a patent for semaglutide micro-particles and their manufacturing method. The essence of this patent is to manufacture differentiated semaglutide micro-particle formulations through the company’s proprietary platform technology, IVL-DrugFluidic.
IVL-DrugFluidic, a source technology owned by Inventizy Lab, implements long-acting injection formulations using polymer micro-particles. It is reported that Inventizy Lab has registered a total of 27 patents related to IVL-DrugFluidic both domestically and internationally.